OnKure Therapeutics (NASDAQ:OKUR) Posts Earnings Results, Misses Expectations By $0.51 EPS

OnKure Therapeutics (NASDAQ:OKUR) released its quarterly earnings data on Monday. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51), Zacks reports.

OnKure Therapeutics Stock Performance

NASDAQ:OKUR traded down $0.06 on Monday, hitting $4.96. The stock had a trading volume of 17,420 shares, compared to its average volume of 82,185. The company has a market cap of $16.58 million, a P/E ratio of -0.41 and a beta of 0.28. The company’s fifty day moving average price is $6.11. OnKure Therapeutics has a 52 week low of $4.57 and a 52 week high of $20.00.

Wall Street Analysts Forecast Growth

OKUR has been the subject of a number of research analyst reports. Leerink Partnrs raised shares of OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Leerink Partners initiated coverage on shares of OnKure Therapeutics in a research note on Thursday, December 5th. They set an “outperform” rating and a $33.00 price target for the company. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $36.00.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.